Oral lopinavir use and human papillomavirus infection in HIV-positive women

Journal of Acquired Immune Deficiency Syndromes

Volumn 70, Issue 2, 2015, Pages e63-e66

  Lahiri, Cecile D ^a   Dugan, Katherine B ^a   Xie, Xianhong ^b   Reimers, Laura ^b   Burk, Robert D ^b   Anastos, Kathryn ^b   Massad, Leslie Stewart ^c   Eltoum, Isam Eldin ^d   Xue, Xiaonan ^b   D'Souza, Gypsyamber ^e   Flowers, Lisa ^a   Palefsky, Joel M ^f   Rahangdale, Lisa ^g   Strickler, Howard D ^b   Ofotokun, Ighovwerha ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d University of Alabama at Birmingham   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOPINAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; CONDOM USE; CONTROLLED STUDY; DRUG USE; FEMALE; GYNECOLOGICAL EXAMINATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN TISSUE; LETTER; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; VIRAL CLEARANCE; VIRUS LOAD; COMPLICATION; HIV INFECTIONS; PAPILLOMAVIRIDAE; UTERINE CERVIX TUMOR; VIROLOGY;

ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; LOPINAVIR; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 84942034112     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000752     Document Type: Letter

References (29)

1. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012; 30(suppl 5): F12-F23.
2. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995; 87: 796-802.
3. Remmink AJ, Walboomers JM, Helmerhorst TJ, et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer. 1995; 61: 306-311.
4. Steben M, Duarte-Franco E. Human papillomavirus infection: epidemiology and pathophysiology. Gynecol Oncol. 2007; 107(2 suppl 1): S2-S5.
5. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12-19.
6. Ahdieh L, Munoz A, Vlahov D, et al. Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women. Am J Epidemiol. 2000; 151: 1148-1157.
7. de Sanjose S, Palefsky J. Cervical and anal HPV infections in HIV positive women and men. Virus Res. 2002; 89: 201-211.
8. Jamieson DJ, Duerr A, Burk R, et al. Characterization of genital human papillomavirus infection in women who have or who are at risk of having HIV infection. Am J Obstet Gynecol. 2002; 186: 21-27.
9. Minkoff H, Feldman J, DeHovitz J, et al. A longitudinal study of human papillomavirus carriage in human immunodeficiency virusinfected and human immunodeficiency virusuninfected women. Am J Obstet Gynecol. 1998; 178: 982-986.
10. Palefsky JM, Minkoff H, Kalish LA, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIVnegative women. J Natl Cancer Inst. 1999; 91: 226-236.
11. Strickler HD, Burk RD, Fazzari M, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst. 2005; 97: 577-586.
12. Sun XW, Ellerbrock TV, Lungu O, et al. Human papillomavirus infection in human immunodeficiency virus-seropositive women. Obstet Gynecol. 1995; 85: 680-686.
13. Sun XW, Kuhn L, Ellerbrock TV, et al. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med. 1997; 337: 1343-1349.
14. Temmerman M, Tyndall MW, Kidula N, et al. Risk factors for human papillomavirus and cervical precancerous lesions, and the role of concurrent HIV-1 infection. Int J Gynaecol Obstet. 1999; 65: 171-181.
15. Minkoff H, Zhong Y, Burk RD, et al. Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Infect Dis. 2010; 201: 681-690.
16. Adler DH, Kakinami L, Modisenyane T, et al. Increased regression and decreased incidence of human papillomavirus-related cervical lesions among HIV-infected women on HAART. AIDS. 2012; 26: 1645-1652.
17. Heard I, Schmitz V, Costagliola D, et al. Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS. 1998; 12: 1459-1464.
18. Heard I, Tassie JM, Kazatchkine MD, et al. Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. AIDS. 2002; 16: 1799-1802.
19. Minkoff H, Ahdieh L, Massad LS, et al. The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. AIDS. 2001; 15: 2157-2164.
20. Batman G, Oliver AW, Zehbe I, et al. Lopinavir up-regulates expression of the antiviral protein ribonuclease L in human papillomavirus-positive cervical carcinoma cells. Antivir Ther. 2011; 16: 515-525.
21. Zehbe I, Richard C, Lee KF, et al. Lopinavir shows greater specificity than zinc finger ejecting compounds as a potential treatment for human papillomavirus-related lesions. Antivir Res. 2011; 91: 161-166.
22. Hampson INMI, Hampson L, Masinde M, et al. A Phase 1/2 trial of a self-applied, nonsurgical treatment for HPV related high grade cervical neoplasia. Paper presented at: oral presentation presented at 11th International Conference on Urban Health; March 5, 2014; Manchester, England.
23. Bacon MC, von Wyl V, Alden C, et al. The women's interagency HIV study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol. 2005; 12: 1013-1019.
24. Kovacs A, Wasserman SS, Burns D, et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet. 2001; 358: 1593-1601.
25. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2009). A Review of Human Carcinogens. Part B: Biological Agents. Lyon, France: IARC. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 100B). Chapter 6, Human papillomaviruses, pp. 255-313.
26. Xue X, Kim MY, Castle PE, et al. A new method to address verification bias in studies of clinical screening tests: cervical cancer screening assays as an example. J Clin Epidemiol. 2014; 67: 343-353.
27. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998; 17: 2265-2281.
28. Dumond JB, Yeh RF, Patterson KB, et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS. 2007; 21: 1899-1907.
29. Pokorna J, Machala L, Rezacova P, et al. Current and novel inhibitors of HIV protease. Viruses. 2009; 1: 1209-1239.